UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of December 2017 (Report no. 1)

Commission File Number: 000-30820

TIKCRO TECHNOLOGIES LTD. (Translation of registrant’s name into English)

7 Sapir Street, 5th floor, Ness Ziona 7403630 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒         Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): N/A

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): N/A

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐        No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- N/A

CONTENTS

This Report on Form 6-K of the registrant consists of the following document, which is attached hereto and incorporated by reference herein, and the first sentence of such document and the GAAP financial information contained in such document are incorporated by reference into the registrant's Registration Statement on Form S-8, Registration No. 333-212579.

Exhibit

Number Description of Exhibit

99.1 Press release: Tikcro Technologies Reports Third Quarter 2017 Results; In-progress of Pre Clinical Trials of Full-Human CTLA-4 Antibodies, dated December 15, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIKCRO TECHNOLOGIES LTD.
	By:	/s/ Aviv Boim
Date: December 18, 2017		Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description of Exhibit
99.1	Press release: Tikcro Technologies Reports Third Quarter 2017 Results; In-progress of Pre Clinical Trials of Full-Human CTLA-4 Antibodies, dated December 15, 2017.